Aligos Pulls Plug On Early-Stage Chronic Hepatitis B Treatment Candidate - Aligos Therapeutics (NASDAQ:ALGS)

Aligos Therapeutics Inc (NASDAQ:ALGS) has discontinued the development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).

To add Benzinga News as your preferred source on Google, click here.

Aligos Therapeutics Inc (NASDAQ:ALGS) has discontinued the development of its drug candidate, ALG-020572, which was being studied in subjects with chronic hepatitis B (CHB).

Dosing in the first CHB cohort of the Phase 1 study was stopped after one subject experienced a serious adverse event (SAE) with a significant increase in alanine aminotransferase (ALT) following multiple dosing of 210 mg ALG-020572 that resulted in a brief hospitalization.
This is one of four CHB subjects in this first cohort who experienced potentially drug-related ALT flares, which were unexpected based on prior experience in nonclinical studies and single-dose safety data in healthy volunteers.
In all four CHB subjects, laboratory parameters and symptoms are improving. The hospitalized subject has been discharged.
With this reprioritization of the company's pipeline and proceeds resulting from Aligos' partnership activities and other cost-saving measures, Aligos believes its cash to provide sufficient resources to fund planned operations into 1H of 2024.
Price Action: ALGS shares are up 1.40% at $2.89 during the market session on the last check Tuesday.

To add Benzinga News as your preferred source on Google, click here.